Nathanael Gray
Nathanael Gray | |
|---|---|
| Alma mater |
|
| Scientific career | |
| Institutions |
|
Nathanael S. Gray is a professor of biological chemistry and molecular pharmacology at Harvard Medical School and professor of cancer biology at Dana-Farber Cancer Institute. His work focuses on synthetic chemistry and novel small molecule inhibitors.
Gray grew up in Zambia, Yemen, India and Sudan and moved to California for high school.[1] Nathanael Gray received his BS and PhD in organic chemistry from UC Berkeley in 1999 where he discovered . After graduating, he worked at the Genomics Institute of the Novartis Research Foundation in San Diego, and after working as a staff scientist and group leader of kinase inhibitor chemistry, he was named director of biological chemistry in 2001. He moved to Harvard Medical School and the Dana-Farber Cancer Institute in 2006.[2] Among the discoveries his lab has made are , an ATP-competitive mTOR inhibitor, , an inhibitor of ERK5, and inhibitors of EGFR, mTor, Bcr-Abl, Mps1, Erk5, b-Raf and Ephrin kinases.[3]
Awards[]
- 2007 National Science Foundation Career award
- 2008 Damon Runyon Foundation Innovator award
- 2010 American Association for Cancer Research for Team Science
- 2011 American Association for Cancer Research Outstanding Achievement Award
- 2011 Eli Lilly Award in Biological Chemistry
- 2011 American Chemical Society award for Biological Chemistry
- 2013 Meyenburg Prize[4]
References[]
- ^ "The Nathanael Gray Laboratory – Nathanael S. Gray, PhD". graylab.dfci.harvard.edu.
- ^ "Dana-Farber Cancer Institute – Researcher Directory – Nathanael Gray, PhD". researchers.dana-farber.org.
- ^ "Nathanael Gray PhD – Parkinson's Disease". The Michael J. Fox Foundation for Parkinson's Research – Parkinson's Disease.
- ^ "Nathanael Gray – International Symposium on Chemical Biology".
Authority control  |
|
|---|
- Living people
- Harvard Medical School faculty
- University of California, Berkeley alumni
- American chemists